On May 9, 2017 EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) reported that the US Food and Drug Administration (FDA) has granted accelerated approval for BAVENCIO (avelumab) Injection for a second indication (Press release, Pfizer, MAY 9, 2017, View Source [SID1234518955]). The full prescribing information for BAVENCIO will be available at www.BAVENCIO.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The full prescribing information for BAVENCIO will be available at www.BAVENCIO.com.

EMD Serono and Pfizer will provide additional details on the approval in a press release to follow.